Industry Research Reports and Market Analysis at MindBranch.com Research Index | Publishers | My Account | Contact Us | About MindBranch
Welcome Guest  (Login/Register) |  0 items
  
Advanced Search > | Tips >
Contact a
Research Assistant

US 800-774-4410
or +1-240-747-3094

Search Assistance >
Matching Industries
Pharmaceutical4

About MindBranch
Government Services
Press Releases
Our Publishers
Our Clients
Publisher Sign-Up


Home > About MindBranch > Market Research Publishers

Biophoenix Limited


Biophoenix Limited

Biophoenix is a biomedical consultancy based in the heart of England, which was founded by Drs Sreten Bogdanovic and Beata Langlands. Originally established with support from the predecessor to the UK's Department for Business, Enterprise and Regulatory Reform (BERR) in 1994, Biophoenix provides detailed, accurate, market and technical information to support decision-making by biotechnology-based enterprises in the healthcare industry. In doing so, Biophoenix relies on its comprehensive in-house bioindustry database and a wide network of contacts. Biophoenix has researched and written over 50 in-depth management/market reports which have been published by clients such as Frost & Sullivan, the London Financial Times, Drug and Market Development Inc, Informa Healthcare (e.g. Scrip and Clinica), and Business Insights (part of Datamonitor). Biophoenix has also audited biotechnology-based enterprises with regard to the risk of intellectual property litigation on behalf of several Lloyds of London insurers.



3 publications





Title Published Price
Biosimilars and Biobetters: Positioning for a New Market Jul 2009 $3,230.00

Patents on the earliest approved biologics, including many blockbusters with over $1 billion in annual sales, have started to expire. This has opened the market to biosimilar competition, initially in the EU, where a total more...
Published by: Biophoenix Limited | Search inside this report

Apoptosis 2009: Opportunities in Cancer and Other Diseases Feb 2009 $3,000.00

Apoptosis is regarded as the major mode of cell death in cancer and should therefore be considered as a potential target when developing new antineoplastic drugs. An increasing number of companies are doing so, and more...
Published by: Biophoenix Limited

Dyslipidemia: Opportunities in Cardiovascular Risk Reduction Jul 2008 $3,000.00

This report examines trends in the $36 billion dyslipidemia market, which is poised for transformation with the advent of novel combination products and biopharmaceuticals. Cholesterol (LDL and HDL) and triglycerides need to be controlled in more...
Published by: Biophoenix Limited


Title Published Price



Privacy Policy | Terms & Conditions | Site Map | Return Policy | Help FAQs
Copyright © 1999-2008, All Rights Reserved, MindBranch.com
Trust-e Logo
Phone: 800-774-4410 (US) or +1-240-747-3094 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: support@mindbranch.com